PETVIVO HOLDINGS INC - PETV STOCK NEWS

PetVivo Holdings (OTCQB: PETV) announced its participation in the American Association of Equine Practitioners (AAEP) convention from December 8-10, 2024, in Orlando, Florida. The company will showcase Spryng™ with OsteoCushion™ Technology, their lead product for joint pain management. Spryng is an intra-articular injectable veterinary device using sterilized, extra-cellular matrix microparticles that integrate with the animal's subsynovial tissue to restore proper joint mechanics. The product aids in managing noninfectious joint pain, including joint instability, degenerative joint disease, and osteoarthritis.

PetVivo Holdings (OTCQB: PETV) reported fiscal Q2 2025 results with revenues of $201,000, up 62% sequentially but down 3% year-over-year. The company is transitioning from primarily equine market focus to include the larger companion animal market. Distributor sales increased 24% to $169,000. Gross profit declined 3% to $180,000, maintaining an 89.5% margin. Net loss improved to $2.2 million ($0.11 per share) compared to $3.7 million ($0.28 per share) year-ago. The company reiterated its fiscal 2025 revenue outlook of approximately $1.5 million, representing 50% growth. Cash position was $126,000 as of September 30, 2024, with additional $312,500 raised post-quarter.

PetVivo Holdings (OTCQB: PETV) announced it will release its financial results for the second quarter ended September 30, 2024, on Thursday, November 14, 2024, after market close. The biomedical device company, focused on commercializing innovative medical therapeutics for animals, will host a conference call at 4:00 p.m. CT (5:00 p.m. ET) on the same day to discuss the results. A webcast replay will be available through the company's Investor Relations website.

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) has appointed Cindy Gill as field veterinary business development manager for Oklahoma, Arkansas, and northern Texas. Gill brings significant veterinary industry experience, having worked for companies like Lintbells, Midwest Veterinary Supply, and Merck. She will focus on expanding sales of PetVivo's flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary injectable medical device for managing osteoarthritis in animals.

Spryng has shown effectiveness in improving medical outcomes for animals with lameness and joint-related afflictions. It has been used by over 800 veterinary clinics across 50 states, with more than 10,000 syringes distributed nationwide. This success reflects the growing U.S. animal health market, projected to reach $11.3 billion by 2030.

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) has appointed Skylor Walker as the new field veterinary business development manager for Louisiana and southern Texas. Walker brings significant experience in veterinary sales, previously working with Contura International and ADP. She will focus on expanding sales of PetVivo's flagship product, Spryng™ with OsteoCushion™ Technology, a revolutionary injectable medical device for managing osteoarthritis and other musculoskeletal conditions in animals.

Spryng has shown effectiveness in improving medical outcomes for animals with lameness and joint-related afflictions. The product is now used by over 800 veterinary clinics across 50 states, with more than 10,000 Spryng syringes distributed nationwide. This success aligns with the projected growth of the U.S. animal health market, expected to reach $11.3 billion by 2030.

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW), a provider of biomedical therapeutics for animals, was featured in the Sight & Sound's Visionaries Series on Bloomberg Television. The episode highlighted Spryng™ with OsteoCushion™ Technology, PetVivo's flagship product for managing osteoarthritis and other musculoskeletal conditions in animals. The program aired on September 5 and was distributed across various digital platforms, reaching a wide audience.

PetVivo CEO John Lai emphasized the transformative impact of Spryng on animal joint health. The company has achieved significant milestones, with Spryng now used in over 800 veterinary clinics across 50 states, resulting in the distribution of more than 10,000 Spryng syringes nationwide since its commercialization. This success aligns with the projected growth of the U.S. animal health market, expected to reach $11.3 billion by 2030.

PetVivo Holdings, Inc. (OTCQB: PETV) has appointed Dr. Kirsty Husby as senior technical services veterinarian to support the growing adoption of its flagship product, Spryng with OsteoCushion™ Technology. Dr. Husby, a board-certified veterinary surgeon with over a decade of experience, will help create broader understanding among veterinarians about Spryng's benefits in treating osteoarthritis in companion animals.

PetVivo recently achieved a significant milestone with Spryng being used by more than 800 veterinary clinics across 50 states, resulting in the distribution of over 10,000 Spryng syringes nationwide. This success has positioned the company to potentially double its revenue in the current fiscal year. Dr. Husby's appointment aims to further accelerate market adoption and improve the quality of life for animals living with osteoarthritis and other lameness issues.

PetVivo Holdings, Inc. (OTCQB: PETV & PETVW), a biomedical device company focusing on innovative medical devices for companion animals, has appointed Scot Cave as its new Field Veterinary Business Development Manager for the Northwest Region of the United States. Cave brings over 25 years of animal health sales and management experience to PetVivo, including leadership roles in the U.S. Army and positions with veterinary companies like Covetrus, Medivet, KindredBio, and Merck.

CEO John Lai expressed confidence that Cave's expertise will help PetVivo meet its primary objective of expanding sales. Cave, who holds a Bachelor of Science in Biology from Ferris State University, is enthusiastic about promoting Spryng, PetVivo's veterinary medical device that addresses joint-related afflictions by targeting cartilage loss or damage rather than just treating symptoms.

PetVivo Holdings, Inc. (OTCQB: PETV, PETVW) has partnered with Orthobiologic Innovations (OBI) to advance clinical trials, product development, and marketing of Spryng™ with OsteoCushion™ Technology, their lead animal osteoarthritis medical device. Sherman O. Canapp, Jr. and Debra Canapp, OBI's leadership, have joined PetVivo's advisory board, bringing extensive experience in veterinary orthopedics and sports medicine.

OBI will assist PetVivo in coordinating clinical trials for Spryng, focusing on joint-related issues in canine patients' elbows and stifles (knees). These studies will evaluate the effectiveness of intra-articular injections of collagen-elastin hydrogel microparticles (CEHM) in dogs with osteoarthritis and those undergoing TPLO procedures. This collaboration aims to enhance product awareness and accelerate market adoption of Spryng across the United States.